Active clinical trials for "Schizophrenia"

Background: - Schizophrenia is associated with cognitive impairment in different parts of the brain, including those associated with learning and memory. The brain activity associated with these impairments, however, is poorly understood. Researchers are interested in studying how the brain chemical dopamine, which is involved in responding to incentives and rewards like money or food, works differently in the brains of people who have schizophrenia. Objectives: - To study reward processing in individuals with schizophrenia who are taking different types of medication, compared with healthy volunteers. Eligibility: - Individuals between 18 and 55 years of age who (a) have been diagnosed with schizophrenia/schizoaffective disorder and are taking the antipsychotic medication clozapine, (b), have been diagnosed with schizophrenia/schizoaffective disorder and are taking a different second-generation antipsychotic, or (c) are healthy volunteers. Design: This study will involve one screening visit and one or more visits for testing and functional magnetic resonance imaging (fMRI) scans. During the screening visit, participants will complete questionnaires and provide information about their physical and psychological health. Participants will receive training in the tasks to be performed at the scanning sessions during the screening visit. During the fMRI scans, participants will complete one or two of four possible reward-based tasks: A task that enables participants to win money based on their response to a target item. A task that provides small amounts of juice over specific time intervals, followed by a procedure to be completed outside the scanner. A task that involves choosing figures or shapes and winning money based on responses. A game of chance involving predictions based on shapes shown on a screen. Participants will also provide blood samples for research and testing.

The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improve the relapse prevention in schizophrenic outpatients

This study is the first hospital-based, cross-sectional study to discuss the prevalence of obesity among 710 inpatients with schizophrenia.

Muscle evoked potentials (MEP) are supposed to different in schizophrenic and depressed patients, compared to a sample of healthy volunteers. Transcranial Magnetic Stimulation (TMS)-evoked MEP are measured in all three groups at baseline and after tDCS (2 mA, 20 minutes). MEP amplitudes are supposed to normalize quickly in healthy volunteers, to stay diminished in depressed patients and to stay elevated in schizophrenic patients. These differences should disappear after regular pharmacological treatment. Outcome measures will be done in week 2 and week 4.

There are two research purposes of this study. One is to explore which psychosocial issue or biological issue would affect the social function among people with schizophrenia. The other one is to explore which social function would affect the job tenure among people with schizophrenia. There are 60 participants diagnosed with schizophrenia and divided into two groups, employment and unemployment. we will use several social function tests to collect social function, PANSS to evaluate their psychotic symptoms. And then we will compare and analysis the data through statistic software. Finally, we will have he answer about how social skills affect the social function and which social skill would affect the job tenure among people with schizophrenia.

With this observational study we want to examine if the intensity of agitation, the intensity of psychotic symptoms and the presence of sleeping disorder predict the success of the treatment with a atypical antipsychotic after 12 weeks of treatment with patients with a psychotic and/or manic episode. In this study it will be examined what the percentage of patients with a 2-point improvement at the CGI-scale is. Of these group, the responders, retrospective the profile of the responders will be analysed (key-factors and confounders). PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

To analyse the progress of modifiable metabolic risk factors (Blood pressure, cigarette smoking, waist perimeter, BMI, glycemia and lipidic profile) in schizophrenic patients with overweight for 12 months. To analyse the perceived health status and the level of functioning and disability of patients with schizophrenia and overweight and their progress at 3, 6 and 12 months. To assess the progress of the symptoms of the disease at 6 and 12 months.

'Real life' retrospective patient cases (10) to provide an objective and robust analytical report of patient management and prescriptions behaviours for Schizophrenia, Bipolar disorders and Major depressive disorders.

This study aims to determine how clozapine treatment improves neuronal measures of sensory gating in subjects with schizophrenia.

The purpose of this study is to establish and validate a scale/model that can be used to evaluate the duration of time and factors between short term hospital treatment and subsequent relapse periods in patients with schizoaffective/schizophreniform disorders.